What is Mounjaro?||Ozempic vs Mounjaro

Mounjaro Mounjaro is an injectable prescription medication containing tirzepatide, which belongs to a class of diabetes medications known as GLP-1 agonists, and GIP (glucose-dependent insulinotropic polypeptides). This medication is used along with diet and exercise to improve blood glucose levels in adults with type 2 diabetes mellitus. However, it is not suitable for use in patients with type 1 diabetes. Mounjaro is not a weight loss medication. However, people taking Mounjaro have lost up to 25 pounds in clinical trials. Mounjaro has compared Ozempic 1 mg in a 40-week study of 1879 adults with type 2 diabetes who were also taking metformin and had a baseline A1C of 8.3 percent. Mounjaro reduced their A1C by 2.0 percent on the 5-mg dose, 2.2 percent on the 10-mg dose, and 2.3 percent on the 15-mg dose. The A1C of people taking the Ozempic 1-mg dose was reduced by 1.9 percent on average. – On May 13, 2022, The FDA approved Mounjaro Injection, manufactured by Eli Lilly, a new once-weekly GIP, and GLP-1 receptor agonist to improve glycemic control in adults with type 2 diabetes.  Mounjaro, the first and only FDA-approved GIP and GLP-1 receptor agonist, is a single molecule that activates the

Read More